Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Plasma Cell Dyscrasias”

37 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 37 results

Not applicableStudy completedNCT02741999
What this trial is testing

A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early

Who this might be right for
Plasma Cell DyscrasiaMonoclonal Gammopathy
Tufts Medical Center 20
Not applicableLooking for participantsNCT06760052
What this trial is testing

Longitudinal Data Registry of Plasma Cell Dyscrasia

Who this might be right for
Multiple Myeloma and Other Plasma Cell Neoplasms
Shanghai Zhongshan Hospital 2,000
Testing effectiveness (Phase 2)Study completedNCT00048412
What this trial is testing

Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H

Who this might be right for
Myelodysplastic DisordersLeukemiaMultiple Myeloma+2 more
Baylor College of Medicine 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07751471
What this trial is testing

BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)

Who this might be right for
AL Amyloidosis
Institute of Hematology & Blood Diseases Hospital, China 20
Large-scale testing (Phase 3)Active Not RecruitingNCT04512235
What this trial is testing

Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Who this might be right for
AL Amyloidosis
Alexion Pharmaceuticals, Inc. 281
Testing effectiveness (Phase 2)Study completedNCT00821249
What this trial is testing

ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaPlasma Cell Leukemia
Pfizer 55
Large-scale testing (Phase 3)Study completedNCT03480360
What this trial is testing

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Who this might be right for
Acute Myeloid LeukemiaChronic Lymphocytic LeukemiaChronic Myeloid Leukemia+6 more
Dartmouth-Hitchcock Medical Center 21
Large-scale testing (Phase 3)WithdrawnNCT02155634
What this trial is testing

Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma

Who this might be right for
Multiple MyelomaNeoplasmsPlasma Cells+4 more
Celgene
Very early researchNot Yet RecruitingNCT07365059
What this trial is testing

Safety and Efficacy of GPRC5D CAR-T Cell Therapy in Relapsed/Refractory Plasma Cell Disorders

Who this might be right for
Plasma Cell Dyscrasias
Qi deng 18
Early research (Phase 1)Study completedNCT00952237
What this trial is testing

Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF

Who this might be right for
Non-Hodgkin's LymphomaHodgkin's DiseaseMultiple Myeloma+2 more
Dartmouth-Hitchcock Medical Center 13
Post-approval studies (Phase 4)Study completedNCT04080531
What this trial is testing

Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders

Who this might be right for
Plasma Cell Neoplasm
Emory University 165
Not applicableLooking for participantsNCT01408225
What this trial is testing

Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource

Who this might be right for
Plasma Cell DyscrasiasMonoclonal Gammopathy of Undetermined SignificanceAL Amyloidosis+1 more
Ohio State University Comprehensive Cancer Center 5,000
Not applicableStudy completedNCT05032339
What this trial is testing

Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyric™ Flow Cytometer

Who this might be right for
Plasma Cell Disorder
Becton, Dickinson and Company 208
Not applicableWithdrawnNCT05362331
What this trial is testing

Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy

Who this might be right for
LymphomaLeukemiaPlasma Cell Dyscrasia
University of California, San Francisco
Testing effectiveness (Phase 2)Looking for participantsNCT07075510
What this trial is testing

Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders

Who this might be right for
Plasma Cell Disorder
University of Maryland, Baltimore 30
Testing effectiveness (Phase 2)Study completedNCT01447914
What this trial is testing

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple Myeloma
National Cancer Institute (NCI) 16
Testing effectiveness (Phase 2)Study completedNCT02556931
What this trial is testing

Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

Who this might be right for
Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaSmall Lymphocytic Lymphoma+11 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 117
Testing effectiveness (Phase 2)Ended earlyNCT00942422
What this trial is testing

Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell NeoplasmPrecancerous Condition
Barbara Ann Karmanos Cancer Institute 8
Not applicableNot Yet RecruitingNCT06286215
What this trial is testing

Registry of Patients With Plasma Cell Disorders

Who this might be right for
Plasma Cell Disorders
Siriraj Hospital 750
Early research (Phase 1)Looking for participantsNCT06313502
What this trial is testing

High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders

Who this might be right for
Plasma Cell Disorder
University of Arkansas 18
Next Page